Log in to search using one of your social media accounts:

 

MERS antibodies produced in cattle safe, treatment well tolerated in phase 1 trial

(NIH/National Institute of Allergy and Infectious Diseases) An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial led by National Institutes of Health scientists and their colleagues. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

CONCLUSION: Children with grass pollen induced rhinitis during exposure to pollen have an incidence of endoscopically confirmed acute rhinosinusitis comparable to non-allergic children. This suggests that grass pollen induced rhinitis is a negligible risk factor for acute rhinosinusitis. PMID: 29343309 [PubMed - as supplied by publisher]
Source: Journal of Laryngology and Otology - Category: ENT & OMF Tags: J Laryngol Otol Source Type: research
We present a case of a 73 yo male with severe lidocaine allergy who successfully underwent bronchoscopy with chloroprocaine topical anesthesia and discuss alternative topical anesthetic agents that may be used in this special situation. PMID: 29349036 [PubMed]
Source: Respiratory Care - Category: Respiratory Medicine Authors: Tags: Respir Med Case Rep Source Type: research
Opinion statementMast cell activation syndromes (MCAS) are an emerging entity that includes a heterogeneous group of diseases presenting with typical signs and symptoms secondary to the release of mast cell (MC) mediators. Triggering factors underlying the activation of mast cells show a wide variability, and episodes of MC-mediator release are usually triggered by idiopathic or by mixed causes, which makes avoidance recommendations difficult to devise. Sometimes, environmental or occupational exposures are responsible for MC activation. In this article, we review the main workplace environment eliciting factors described ...
Source: Current Treatment Options in Allergy - Category: Allergy & Immunology Source Type: research
Publication date: Available online 19 January 2018 Source:The Journal of Allergy and Clinical Immunology: In Practice Author(s): Tukisa D. Smith, Jennifer Camacho, Julie Wang
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Conclusions Skin testing for potential ICM hypersensitivity can identify safe alternative(s) for ICM re-exposure especially in patients with an immediate hypersensitivity reaction and/or skin test-proven ICM drug allergy. Reactions on re-exposure were infrequent, mostly milder, and occurred in some patients despite premedication.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: Available online 19 January 2018 Source:The Journal of Allergy and Clinical Immunology: In Practice Author(s): Usama Bin Nasir, Aswini Kumar, Arti Easwar
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Conclusion: The prevalence of LAR patients in Southern China was 7.7%. Pollen was the most common sensitizing allergen for the local LAR patients, which differs from Caucasian studies, in which house dust mite was the dominant sensitizing allergen. Monosensitization was the predominant pattern in both AR and LAR.Int Arch Allergy Immunol
Source: International Archives of Allergy and Immunology - Category: Allergy & Immunology Source Type: research
ConclusionIn line with the One Health concept, covering human health, animal health and environmental health, allergen microarrays provide novel information on the allergen sensitization patterns of the companion animals around us, which may form a basis for allergen‐specific preventive and therapeutic concepts.This article is protected by copyright. All rights reserved.
Source: Allergy - Category: Allergy & Immunology Authors: Tags: Original Article: Experimental Allergy and Immunology Source Type: research
(NIH/National Institute of Allergy and Infectious Diseases) NIH scientists and colleagues report that an experimental vaccine given six weeks before exposure to Middle East respiratory syndrome coronavirus (MERS-CoV) fully protects rhesus macaques from disease. The vaccine also generated potentially protective MERS-CoV antibodies in blood drawn from vaccinated camels. MERS-CoV, which causes pneumonia deep in the lungs, emerged in 2012 and has sickened more than 1,400 people and killed 500, mostly in the Middle East and Asia.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
Antibody against MERS Transmission EM of MERS-CoV. Image courtesy of National Institute of Allergy and Infectious Diseases. Middle East Respiratory Syndrome (MERS) is a severe infection of the lower respiratory tract caused by the MERS coronavirus (MERS-CoV), which has been responsible for over 1,300 human infections and 500 deaths since...
Source: Proceedings of the National Academy of Sciences - Category: Science Tags: This Week in PNAS Source Type: research
More News: Allergy | Allergy & Immunology | Clinical Trials | Coronavirus | Infectious Diseases | MERS | Middle East Health | National Institutes of Health (NIH) | Respiratory Medicine